PSL/CYA therapy for early onset of VKH disease

INTERVENTION: arm mPSL: mPSL (1000mg) given on day 1‐3, and then oral PSL gradually decreasing from 40mg/day arm mPSL+CYA: with the above‐therapy, CYA (3mg/kg/day) given from day 4 CONDITION: Vogt‐Koyanagi‐Harada disease ; Vogt‐Koyanagi‐Harada disease PRIMARY OUTCOME: recurrence of uveitis; ‐inflammation of anterior chamber; ‐choroidal fold; ‐SRD SECONDARY OUTCOME: ‐frequency of side effects; ‐period from the start of therapy to the disappearance of inflammatory findings INCLUSION CRITERIA: 1. Early onset of Vogt‐Koyanagi‐Harada (VKH) disease with all of a)‐d) a) within 4 weeks from onset b) anterior chamber cells less than or equal to 2+ c) with typical serous retinal detachment (SRD) d) without sunset glow fundus 2. Complete or Incomplete type of VKH disease 3. Presence of cerebrospinal fluid pleocytosis or meningeal irritating sign except for headache 4. Able to receive treatment within 4 weeks from onset 5. Written informed consent